Ignite Creation Date:
2024-05-06 @ 1:39 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04082364
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-16
First Post:
2019-09-05
Brief Title:
Combination Margetuximab Retifanlimab Tebotelimab and Chemotherapy Phase 23 Trial in HER2 GastricGEJ Cancer
Sponsor:
MacroGenics
Organization:
MacroGenics
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-09-30
Start Date Type:
ACTUAL
Primary Completion Date:
2024-01-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-06
Completion Date Type:
ESTIMATED
First Submit Date:
2019-09-05
First Submit QC Date:
September 5 2019
Study First Post Date:
2019-09-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-13
Last Update Post Date:
2024-05-16
Last Update Post Date Type:
ACTUAL